PURPOSE: The purpose of this study was to determine the incidence of pain flare (PF) in patients receiving spine stereotactic body radiotherapy (SBRT) treated with prophylactic oral dexamethasone (DEX) 1 h before and for 4 days following SBRT. METHODS: Forty-seven patients were accrued on this prospective observational study. The first cohort of 24 patients was treated with 4 mg, while a second cohort of 23 patients treated with 8 mg of DEX. The Brief Pain Inventory (BPI) was used to score pain and functional interference each day during SBRT and for 10 days following. Comparisons between the 4 and 8 mg cohorts, in addition to our previously reported steroid naïve patients post SBRT (n = 41), were also performed. RESULTS: The total incidence of PF was 19 % (9/47). The incidence in the 4 and 8 mg cohorts was 25 % (6/24) and 13 % (3/23), respectively, and the difference was not statistically significant (p = 0.46). Comparing functional interference, the 4 mg cohort had better profile in walking ability (p < 0.005) and relationships with others (p < 0.035) compared to the 8 mg cohort. Compared to our previously reported steroid naïve cohort, prophylactic DEX significantly reduced the incidence of PF (68 vs. 19 %, p < 0.0001, respectively), patients had lower worst pain scores, and improved general activity interference outcome. CONCLUSION: We recommend prophylactic DEX for patients treated with spine SBRT. Our current practice is based on the 4 mg protocol primarily due to the improved functional interference outcomes. A randomized trial is required to finalize the optimal regimen and schedule.
PURPOSE: The purpose of this study was to determine the incidence of pain flare (PF) in patients receiving spine stereotactic body radiotherapy (SBRT) treated with prophylactic oral dexamethasone (DEX) 1 h before and for 4 days following SBRT. METHODS: Forty-seven patients were accrued on this prospective observational study. The first cohort of 24 patients was treated with 4 mg, while a second cohort of 23 patients treated with 8 mg of DEX. The Brief Pain Inventory (BPI) was used to score pain and functional interference each day during SBRT and for 10 days following. Comparisons between the 4 and 8 mg cohorts, in addition to our previously reported steroid naïve patients post SBRT (n = 41), were also performed. RESULTS: The total incidence of PF was 19 % (9/47). The incidence in the 4 and 8 mg cohorts was 25 % (6/24) and 13 % (3/23), respectively, and the difference was not statistically significant (p = 0.46). Comparing functional interference, the 4 mg cohort had better profile in walking ability (p < 0.005) and relationships with others (p < 0.035) compared to the 8 mg cohort. Compared to our previously reported steroid naïve cohort, prophylactic DEX significantly reduced the incidence of PF (68 vs. 19 %, p < 0.0001, respectively), patients had lower worst pain scores, and improved general activity interference outcome. CONCLUSION: We recommend prophylactic DEX for patients treated with spine SBRT. Our current practice is based on the 4 mg protocol primarily due to the improved functional interference outcomes. A randomized trial is required to finalize the optimal regimen and schedule.
Authors: Xin Shelley Wang; Laurence D Rhines; Almon S Shiu; James N Yang; Ugur Selek; Ibrahima Gning; Ping Liu; Pamela K Allen; Syed S Azeem; Paul D Brown; Hadley J Sharp; David C Weksberg; Charles S Cleeland; Eric L Chang Journal: Lancet Oncol Date: 2012-01-27 Impact factor: 41.316
Authors: A Sahgal; D Roberge; D Schellenberg; T G Purdie; A Swaminath; J Pantarotto; E Filion; Z Gabos; J Butler; D Letourneau; G L Masucci; L Mulroy; A Bezjak; L A Dawson; M Parliament Journal: Clin Oncol (R Coll Radiol) Date: 2012-05-24 Impact factor: 4.126
Authors: Arjun Sahgal; Mark Bilsky; Eric L Chang; Lijun Ma; Yoshiya Yamada; Laurence D Rhines; Daniel Létourneau; Matthew Foote; Eugene Yu; David A Larson; Michael G Fehlings Journal: J Neurosurg Spine Date: 2010-12-24
Authors: Marcelo V R Cunha; Ameen Al-Omair; Eshetu G Atenafu; Giuseppina Laura Masucci; Daniel Letourneau; Renee Korol; Eugene Yu; Peter Howard; Fiona Lochray; Leodante B da Costa; Michael G Fehlings; Arjun Sahgal Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-01 Impact factor: 7.038
Authors: A Sahgal; D Chou; C Ames; L Ma; K Lamborn; K Huang; C Chuang; A Aiken; P Petti; P Weinstein; D Larson Journal: Technol Cancer Res Treat Date: 2007-12
Authors: Arjun Sahgal; Lijun Ma; Iris Gibbs; Peter C Gerszten; Sam Ryu; Scott Soltys; Vivian Weinberg; Shun Wong; Eric Chang; Jack Fowler; David A Larson Journal: Int J Radiat Oncol Biol Phys Date: 2009-09-16 Impact factor: 7.038
Authors: Arjun Sahgal; Eshetu G Atenafu; Sam Chao; Ameen Al-Omair; Nicholas Boehling; Ehsan H Balagamwala; Marcelo Cunha; Isabelle Thibault; Lilyana Angelov; Paul Brown; John Suh; Laurence D Rhines; Michael G Fehlings; Eric Chang Journal: J Clin Oncol Date: 2013-08-19 Impact factor: 44.544
Authors: Hubert Y Pan; Pamela K Allen; Xin S Wang; Eric L Chang; Laurence D Rhines; Claudio E Tatsui; Behrang Amini; Xin A Wang; Nizar M Tannir; Paul D Brown; Amol J Ghia Journal: Int J Radiat Oncol Biol Phys Date: 2014-09-13 Impact factor: 7.038
Authors: Zain A Husain; Arjun Sahgal; Eric L Chang; Pejman Jabehdar Maralani; Charlotte D Kubicky; Kristin J Redmond; Charles Fisher; Ilya Laufer; Simon S Lo Journal: CNS Oncol Date: 2017-07-18
Authors: Ehsan H Balagamwala; Mihir Naik; Chandana A Reddy; Lilyana Angelov; John H Suh; Toufik Djemil; Anthony Magnelli; Samuel T Chao Journal: J Radiosurg SBRT Date: 2018
Authors: Chia-Lin Tseng; Wietse Eppinga; Raphaele Charest-Morin; Hany Soliman; Sten Myrehaug; Pejman Jabehdar Maralani; Mikki Campbell; Young K Lee; Charles Fisher; Michael G Fehlings; Eric L Chang; Simon S Lo; Arjun Sahgal Journal: Global Spine J Date: 2017-04-06